A 2019 systematic review pooling data from 22 controlled studies found that hydroxyapatite-coated titanium implants achieved bone-to-implant contact (BIC) ratios averaging 68.4% at 12 weeks post-implantation — compared to 51.2% for uncoated titanium surfaces. The gap is clinically significant, but the more instructive finding was internal to the HAP-coated group: implants with coating crystallinity above 70% outperformed those with amorphous or mixed-phase layers by 15–22 percentage points in early fixation torque tests. Deposition method, not HAP presence alone, is the controlling variable.
Why Uncoated Titanium Falls Short in Early Osseointegration
Titanium and its alloys (primarily Ti-6Al-4V) remain the dominant substrate for orthopaedic and dental implants due to their mechanical strength and corrosion resistance. However, native titanium presents a bioinert oxide surface (TiO₂) that supports fibrous tissue attachment rather than direct bone apposition. In load-bearing applications — particularly during the critical 4–12 week healing window — fibrous encapsulation rather than osseointegration is associated with implant micro-motion, stress shielding, and long-term failure risk.
Bone is approximately 60–70% hydroxyapatite by dry weight (Ca₁₀(PO₄)₆(OH)₂), and osteoblast activity is strongly upregulated on calcium phosphate surfaces that mimic the extracellular matrix. A surface-bound HAP layer creates a chemically familiar environment that promotes preferential adsorption of bone morphogenic proteins and fibronectin — scaffolding proteins that anchor differentiating osteoblasts. This is the biological rationale for HAP coating: it is not a passive filler but a surface-active interface that modulates the implant’s protein adsorption profile from day one post-implantation.
Deposition Methods: Plasma-Spray, Biomimetic, and Electrochemical Approaches
The most commercially established method is atmospheric plasma-spray (APS), in which HAP powder is projected through a plasma torch at temperatures exceeding 10,000°C onto the titanium substrate, forming a coating typically 100–200 µm thick. APS is fast and scalable, but the extreme thermal conditions partially decompose HAP into secondary calcium phosphate phases — tricalcium phosphate (TCP), tetracalcium phosphate (TTCP), and calcium oxide — alongside residual amorphous content. These mixed-phase coatings dissolve non-uniformly in physiological fluid, releasing calcium ions in pulses rather than a sustained gradient, creating localised pH excursions and inconsistent osteoblast signalling.
Biomimetic deposition (simulated body fluid, or SBF, coating) operates at physiological temperatures (36–37°C) by immersing the substrate in a supersaturated calcium-phosphate solution. The resulting layer is thinner (1–10 µm), uniform in crystal phase, and closely mimics stoichiometric HAP (Ca/P ≈ 1.67). Because the process avoids high temperatures, decomposition to secondary phases is eliminated. The trade-off is adhesion strength, which is lower than plasma-spray — a meaningful consideration for high-load orthopaedic applications.
Electrochemical deposition and pulsed laser deposition (PLD) occupy intermediate positions. Electrochemical methods allow fine control of Ca/P ratio and porosity at sub-micron scale, making them well-suited for nano-HAP coating research. PLD produces dense, highly crystalline coatings with strong substrate adhesion but at lower throughput, currently limiting it to research and premium implant segments.
Crystal Phase and Ca/P Ratio: The Performance Variables Procurement Teams Miss
Crystallinity — the proportion of deposited material in ordered hydroxyapatite phase versus amorphous calcium phosphate — directly controls dissolution kinetics. Amorphous calcium phosphate dissolves approximately 10–20× faster than stoichiometric crystalline HAP in physiological saline. In a coating context, an amorphous-heavy plasma-spray layer may delaminate or resorb before adequate bone apposition is established, creating a gap at the bone-implant interface during the precise window when integration should be consolidating.
The Ca/P molar ratio adds a second dimension. Stoichiometric HAP has a Ca/P of 1.67; calcium-deficient HAP (Ca/P 1.5–1.6) is more soluble and biologically resorbable — advantageous in degradable scaffolds, but generally undesirable in a permanent implant coating intended to remain stable over decades. Procurement specifications for HAP coating powder should therefore include minimum crystallinity (typically ≥70% by XRD), Ca/P ratio tolerance (1.65–1.70), and maximum secondary phase content. These parameters are not captured by simple purity certificates, yet they are the primary determinants of in vivo coating performance.
Clinical Evidence: What Randomised Trials and Long-Term Follow-Up Show
The clinical literature on HAP-coated implants spans three decades. A systematic review published in the Journal of Clinical Periodontology examined 14 RCTs comparing HAP-coated versus uncoated titanium dental implants across 5-year follow-up periods. HAP-coated implants showed lower marginal bone loss (mean difference −0.18 mm at 5 years, 95% CI −0.31 to −0.04), with the effect size strongest in patients with type 2 diabetes and smokers — populations where compromised vascularity slows native osseointegration and where a surface-active calcium phosphate interface provides the greatest relative benefit.
In the orthopaedic context, a prospective cohort study of HA-coated cementless hip stems (n=302, 10-year follow-up) reported a 97.4% survival rate with no aseptic loosening events attributable to coating failure — compared to historical controls in the low 90s for uncoated porous stems. Critically, the study protocol specified plasma-spray HAP with crystallinity ≥75% sourced from a single Japanese supplier, underscoring how supplier-side quality control translates directly into implant-level outcomes at the clinical level.
Procurement Specifications for OEM Biomaterial Manufacturers
For OEM teams sourcing HAP powder for coating applications — whether for dental implant contract manufacturing or orthopaedic device supply chains — the most common specification gap is at the powder characterisation stage. Many suppliers report elemental Ca/P purity ratios without specifying phase composition by X-ray diffraction, leaving manufacturers exposed to lot-to-lot crystallinity variation that directly affects post-spray coating performance.
Minimum specifications worth building into procurement contracts include:
- Crystallinity ≥70% by XRD (≥90% preferred for biomimetic and electrochemical processes)
- Ca/P molar ratio 1.65–1.70, confirmed per-lot
- D50 particle size 20–40 µm for APS feedstock; 5–15 µm for electrochemical deposition
- Heavy metal limits below ISO 10993-13 extractable thresholds
- Documented sintering temperature and atmosphere confirming phase-pure synthesis
Suppliers operating under Japanese pharmaceutical-grade GMP — where hydroxyapatite is a regulated Quasi-Drug ingredient with corresponding analytical documentation standards — routinely provide this level of characterisation data as part of standard CoA packages. For implant-grade applications requiring full traceability through regulatory submissions, Japanese-origin HAP represents a lower-risk sourcing decision precisely because the upstream quality infrastructure is already built to the standard the downstream device manufacturer needs.